像火箭一样的微针贴片用于前列腺癌中持续的激素治疗.
Ying-Tzu Chen1,2, Kuan-Ta Chen3, Kai-Jie Yu4,5
1Department of Neurosurgery, Chang Gung Memorial Hospital, Linkou Branch, Taoyuan 33305, Taiwan.
ACS biomaterials science & engineering
|July 18, 2025
概括
一个新型的火箭状微针贴片为前列腺癌 (PCa) 提供持续的激素治疗. 这种无痛的,自给自取的贴片提高了治疗的遵守性和疗效,为PCa管理提供了一个有前途的新方法.
科学领域:
- 生物医学工程 生物医学工程
- 在瘤学瘤学.
- 材料科学 材料科学 材料科学
背景情况:
- 前列腺癌 (PCa) 构成了全球重大健康负担,推动了创新治疗策略的需求.
- 目前用于PCa的激素疗法面临诸多挑战,包括患者不合格和与治疗相关的不适.
研究的目的:
- 开发和评估一种双层火箭型微针贴片 (RLMNP),用于前列腺癌的持续激素治疗.
- 评估RLMNP在阻断雄激素受体信号传递和抑制雄激素合成方面的疗效.
主要方法:
- 制造一个双层RLMNP,集成一个快速释放层 (ZIF-8/双胺) 和一个持续释放层 (Alg-Tyr水凝/goserelin).
- 评估RLMNP的机械特性,皮肤透和药物释放动力学.
- 在体内评估RLMNP在减少瘤体积和延长前列腺癌模型中的生存时间方面的疗效.
主要成果:
- RLMNP表现出强大的机械性能,高效的皮肤透,并控制双重药物释放.
- 在体内研究显示,瘤体积显著减少,生存时间从34天延长到46天.
- RLMNP系统有效地减轻了与传统激素疗法相关的副作用.
结论:
- RLMNP为持续的前列腺癌激素治疗提供了一个有希望的,无痛的,自我管理的平台.
- 这种双重作用的微针贴片改善了治疗结果和患者的遵守.
- 开发的RLMNP技术为在瘤学中基于微针的透皮药物输送的更广泛应用铺平了道路.
更多相关视频
08:38Renal Capsule Xenografting and Subcutaneous Pellet Implantation for the Evaluation of Prostate Carcinogenesis and Benign Prostatic Hyperplasia
Published on: August 28, 2013
25.4K
07:41Author Spotlight: Innovative Microneedle-Based Strategies for Enhanced Exosome Delivery and Stability
Published on: July 12, 2024
2.6K
相关概念视频
01:24Modified-Release Drug Delivery Systems: Site-Targeted
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
01:18Transdermal Drug Delivery Systems
Transdermal drug delivery systems (TDDS) enable the controlled release of drugs across the skin into systemic circulation. They are particularly advantageous for drugs with short half-lives or narrow therapeutic indices, as they maintain consistent plasma concentrations and reduce the risk of subtherapeutic or toxic levels.TDDS are categorized into monolithic, reservoir, and mixed systems. Monolithic systems embed the drug in a polymer matrix, where diffusion governs release. Reservoir systems...